Jefferies rates Vectura at buy

Vectura Group was given a buy rating by Jefferies & Co., Inc. analyst Robin Campbell on news that the company is delivery on its planned product development. Phase 2b trials for both NVA237 and VR004 have been successfully completed. The company also expects raise to raise a fully underwritten £45 million through a stock offering. Shares of the Wiltshire, U.K.-based pharmaceutical company were up 6.00p, or 6.98%, at 92p with a three-month running average of 475,213 shares. (London: VEC)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.